Newsroom

July 22, 2026

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2026 financial results after market close on.

May 5, 2026

Carlsmed® Reports First Quarter 2026 Financial Results

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company.

April 28, 2026

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences. Bank of America Global Healthcare Conference in Las.

April 14, 2026

Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026

CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.

April 1, 2026

Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET.

February 25, 2026

Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine.

February 23, 2026

Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.

February 18, 2026

Carlsmed Announces first corra™ personalized Cervical Plating Procedure

The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the first personalized cervical plating procedure using the corra™

February 11, 2026

Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday.

February 10, 2026

Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo ® Lumbar Bi-lateral Posterior System.

January 12, 2026

Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology.

January 6, 2026

Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal

CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically.

December 16, 2025

Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference

CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San.

December 3, 2025

Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting

First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop CARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S.

November 19, 2025

Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference

CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am.

November 6, 2025

Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance

Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering.

October 23, 2025

Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025.

September 29, 2025

Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary

CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary,

September 22, 2025

Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index

CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that effective after market close on September 22, 2025, it has been added to.

August 28, 2025

Carlsmed® Reports Second Quarter 2025 Financial Results

Q2’25 revenue of $12.1 million , 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions,

August 14, 2025

Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025

CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025.

August 1, 2025

Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures

CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the.

July 28, 2025

Carlsmed’s aprevo® Powers First Personalized Cervical Spine Surgery

CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful completion of the first aprevo ® cervical procedure on July 14, 2025 by Joseph.

July 23, 2025

Carlsmed Announces Pricing of Initial Public Offering

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 22, 2025-- Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at an initial.

July 15, 2025

Carlsmed Announces Launch of Initial Public Offering

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock.

June 26, 2025

Carlsmed Announces Filing of Registration Statement for Proposed Initial Public Offering

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that it has publicly filed a registration statement on Form S-1 with the U.S.

December 4, 2024

Carlsmed Announces FDA Clearance for aprevo® Cervical Breakthrough Fusion Device

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo ® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing.

November 6, 2024

Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver.

October 8, 2024

Carlsmed Adds Industry Veteran, Kevin O’Boyle, to Board of Directors

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including.

August 5, 2024

Carlsmed Announces Favorable Medicare Reimbursement Decision for Spinal Fusions with Custom-Made Anatomically Designed Devices

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, the leader in personalized spine surgery, announced today that in the Hospital Inpatient Prospective Payment System Final Rule for fiscal year 2025, the Centers for Medicare & Medicaid Services (CMS) assigned spinal fusion cases with aprevo ®.

March 18, 2024

Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners. These proceeds will be used to accelerate the commercialization of the aprevo ® personalized spine.

January 8, 2024

Compelling Clinical Data Released for Carlsmed’s aprevo® Technology

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed announced today that new clinical data on its aprevo ® technology has been published in the Global Spine Journal. This landmark study of a patient-matched cohort concluded that the use of aprevo ® personalized interbody devices enables a significant.

September 20, 2023

FDA Grants Second Breakthrough Device Designation for Carlsmed Technology

CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed announced today that the FDA granted Breakthrough Device designation for its aprevo® technology for treatment of patients with cervical spine disease. This is Carlsmed’s second Breakthrough Device designation, complementing the company’s family of.

aprevo® is FDA-cleared in the U.S. for lumbar and cervical spinal fusion indications only.